Neurocrine Biosciences (NBIX) Shares Issued (2010 - 2026)

Neurocrine Biosciences has reported Shares Issued for 17 years, with the latest figure at $23.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Issued fell 26.48% year-over-year to $23.6 million; the trailing twelve-month figure through Mar 2026 stood at $120.9 million (up 43.42% YoY), and the FY2025 full-year result was $129.4 million, up 5.98% from the prior year.
• Shares Issued for Q1 2026 stood at $23.6 million, down from $37.3 million in the prior quarter.
• The five-year high for Shares Issued was $69.9 million in Q1 2024, with the low at $2.6 million in Q2 2022.
• Historically, Shares Issued has averaged $22.7 million across 5 years, with a median of $18.8 million in 2023.
• Annual changes were most pronounced in 2022 — Shares Issued jumped 1266.67% — and 2024, when it sank 71.75%.
• Neurocrine Biosciences' Shares Issued stood at $24.6 million in 2022, then soared by 43.9% to $35.4 million in 2023, then tumbled by 71.75% to $10.0 million in 2024, then soared by 273.0% to $37.3 million in 2025, then plunged by 36.73% to $23.6 million in 2026.
• The last three Shares Issued figures came in at $23.6 million (Q1 2026), $37.3 million (Q4 2025), and $45.6 million (Q3 2025), per Business Quant data.